Company intelligence / Profile preview
MedAbome, Inc.
Fremont, California, United Statesmedabome.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
MedAbome is developing several monoclonal antibody candidates that are currently in preclinical stage, including MAI-002 for stomach cancer, MAI-003 for triple negative breast cancer, and MAI-008 for non-small cell lung cancer.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)Antibody-related therapiesImmunotherapy technologies
- Industry
- Biotech
02
Drug pipeline
22 assets21 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on MedAbome, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedAbome, Inc..